Hipertensión arterial pulmonar en el año 2004

Gibas, 2001, Recommendations on the management of pulmonary hypertension in clinical practice, Heart, 86, 1 Hoeper, 2004, End points and clinical trial designs in pulmonary arterial hypertension clinical and regulatory perspectives, J Am Coll Cardiol, 43, 48S, 10.1016/j.jacc.2004.02.010 Simonneau, 2004, Clinical classification of pulmonary hypertension, J Am Coll Cardiol, 43, 5S, 10.1016/j.jacc.2004.02.037 Dalanzo, 1991, Survival in patients with primary pulmonary hypertension. Results from a national prospective study, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 Barst, 2004, Diagnosis and differential assessment of pulmonary arterial hypertension, J Am Coll Cardiol, 43, 40S, 10.1016/j.jacc.2004.02.032 McGoon, 2004, Screening, early detection, and diagnosis of pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines, Chest, 126, 14S, 10.1378/chest.126.1_suppl.14S McLaughlin, 2004, Prognosis of pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines, Chest, 126, 78S, 10.1378/chest.126.1_suppl.78S Galiè, 2004, Nuevas aportaciones en hipertensión arterial pulmonary, Rev Esp Cardiol, 57, 603, 10.1157/13064184 Archer, 2000, Primary pulmonary hypertension. A vascular biology and translational research «work in progress», Circulation, 102, 2781, 10.1161/01.CIR.102.22.2781 Galie, 2002, Características biopatológicas de la hipertensión arterial pulmonary, Rev Esp Cardiol, 2, 9 Humbert, 2004, Cellular and mollecular pathobiology of pulmonary arterial hypertension, J Am Coll Cardiol, 43, 13S, 10.1016/j.jacc.2004.02.029 Pietra, 2004, Pathologic assessment of vasculopathies in pulmonary hypertension, J Am Coll Cardiol, 43, 25S, 10.1016/j.jacc.2004.02.033 Friedman, 1997, Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension, Circulation, 96, 2782, 10.1161/01.CIR.96.9.2782 Prasad, 2000, Sildenafil in primary pulmonary hypertension, N Engl J Med, 343, 1342, 10.1056/NEJM200011023431814 Michelakis, 2003, Long term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension, Circulation, 108, 2066, 10.1161/01.CIR.0000099502.17776.C2 Ghofrani, 2004, Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension, J Am Coll Cardiol, 43, 68s, 10.1016/j.jacc.2004.02.031 Channick, 2004, Endothelin receptor antagonist in pulmonary arterial hypertensio, J Am Coll Cardiol, 43, 62s, 10.1016/j.jacc.2004.02.042 Dupuis, 2001, Endothelin receptor antagonist in pulmonary hypertension, Lancet, 358, 1113, 10.1016/S0140-6736(01)06298-5 Newman, 2004, Genetic basis of pulmonary arterial hypertension. Current understanding and future directions, J Am Coll Cardiol, 43, 33S, 10.1016/j.jacc.2004.02.028 McGrory, 2004, Methodology and grading for pulmonary hypertension. Evidence Review and Guideline Development, Chest, 126, 11S, 10.1378/chest.126.1_suppl.11S Tei, 1996, Doppler echocardiographic index for assessment of global ventricular function, J Am Coll Cardiol, 26, 838 Raymond, 2002, Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension, J Am Coll Cardiol, 39, 1214, 10.1016/S0735-1097(02)01744-8 Galiè, 2003, Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension, J Am Coll Cardiol, 41, 1380, 10.1016/S0735-1097(03)00121-9 Badesch, 2004, Medical therapy for pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines, Chest, 126, 35S, 10.1378/chest.126.1_suppl.35S Galiè, 2004, Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension, J Am Coll Cardiol, 43, 81S, 10.1016/j.jacc.2004.02.038 Barst, 1996, A comparision of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The primary pulmonary hypertension study group, N Engl J Med, 334, 296, 10.1056/NEJM199602013340504 Badesch, 2000, Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized, controled trial, Ann Intern Med, 132, 425, 10.7326/0003-4819-132-6-200003210-00002 Mc Laughlin, 2002, Survival in primary pulmonary hypertension. The impact of epoprostenol therapy, Circulation, 106, 1477, 10.1161/01.CIR.0000029100.82385.58 Sitbon, 2002, Long term intravenous epoprostenol infusion in primary pulmonary hypertension, J Am Coll Cardiol, 40, 780, 10.1016/S0735-1097(02)02012-0 Rosenzweig, 1999, Long term prostacyclin therapy for pulmonary hypertension with associated congenital heart defects, Circulation, 99, 1858, 10.1161/01.CIR.99.14.1858 Kuo, 1997, Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension, Transplantation, 63, 604, 10.1097/00007890-199702270-00020 Stricker, 1997, Prostayclin for VIH-associated pulmonary hypertension, Ann Intern Med, 127, 1043, 10.7326/0003-4819-127-11-199712010-00030 Kuhn, 2003, Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol, Am J Respir Crit Care Med, 167, 580, 10.1164/rccm.200204-333OC Galie, 2002, The new clinical trials on pharmacological treatment in pulmonary arterial hypertension, Eur Respir J, 20, 1037, 10.1183/09031936.02.05542002 Mc Laughlin, 2003, Efficacy and safety of Treprostinil, an epoprostenol analog for primary pulmonary hypertension, J Cardiovasc Pharmacol, 41, 293, 10.1097/00005344-200302000-00019 Simonneau, 2002, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension, Am J Respir Crit Care Med, 165, 800, 10.1164/ajrccm.165.6.2106079 Badesch, 2004, Prostanoid therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 43, 56S, 10.1016/j.jacc.2004.02.036 Olschewski, 1996, Aerosolized prostacyclin and iloprost in severe pulmonary hypertension, Ann Intern Med, 124, 820, 10.7326/0003-4819-124-9-199605010-00006 Hoeper, 2000, Long term treatment of primary pulmonary hypertension with aerolized iloprost, a prostacyclin analogue, N Engl J Med, 342, 1866, 10.1056/NEJM200006223422503 Olschewski, 2000, Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH study group, Ann Intern Med, 132, 435, 10.7326/0003-4819-132-6-200003210-00003 Olschewski, 2002, Inhaled iloprost in severe pulmonary hypertension, N Engl J Med, 347, 322, 10.1056/NEJMoa020204 Galie, 2002, Effects of beraprost sodium an oral prostacylin analog in patients wiyh pulmonary arterial hypertension: a randomised double-blind placebo-controled clinical trial, J Am Coll Cardiol, 39, 1496, 10.1016/S0735-1097(02)01786-2 Barst, 2003, Beraprost therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 41, 2119, 10.1016/S0735-1097(03)00463-7 Channick, 2001, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study, Lancet, 358, 1119, 10.1016/S0140-6736(01)06250-X Rubin, 2002, Bosentan therapy for pulmonary arterial hypertension, N Engl J Med, 346, 896, 10.1056/NEJMoa012212 Escribano Subías, 2002, Tratamiento médico de la hipertensión pulmonar, Rev Esp Cardiol, 2, 33C Sitbon, 2003, Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. One year follow-up, Chest, 124, 247, 10.1378/chest.124.1.247 Barst, 2004, Sitaxsentan, therapy for pulmonary arterial hypertension, Am J Respir Crit Care Med, 169, 441, 10.1164/rccm.200307-957OC Carlsen, 2002, Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension, AIDS, 16, 1568, 10.1097/00002030-200207260-00021 Sastry, 2004, Clinical efficacy of sildenfilo controlled, double-blind, crossover study, J Am Coll Cardiol, 43, 1149, 10.1016/j.jacc.2003.10.056 Hoeper, 2004, Combination therapy for pulmonaryarterial hypertension: still more question than answers, Eur Respir J, 24, 339, 10.1183/09031936.04.00072104 Ghofrani, 2003, Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension, J Am Coll Cardiol, 42, 158, 10.1016/S0735-1097(03)00555-2 Hoepper, 2003, Bosentan treatment in patients with primary pulmonary hypertension receiving non-parenteral prostanoids, Eur Respir J, 22, 330, 10.1183/09031936.03.00008003 Jiménez, 2004, Eficacia del sildenafilo por vía oral como terapia de rescate en pacientes con hipertensión arterial pulmonar grave en tratamiento crónico con prostaciclina. Resultados a largo plazo, Rev Esp Cardiol, 57, 946, 10.1157/13066455 Stiebellehner, 2003, Long term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension, Chest, 123, 1293, 10.1378/chest.123.4.1293 Humbert, 2004, Combination of Bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2, Eur Respir J, 24, 353, 10.1183/09031936.04.00028404 Barberá, 2002, Indicaciones de trasplante 1998, Am J Respir Crit Care Med, 158, 335, 10.1164/ajrccm.158.1.15812 Doyle, 2004, Surgical treatments/interventions for pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines, Chest, 126, 63S, 10.1378/chest.126.1_suppl.63S Newman, 2004, Pulmonary arterial hypertension future directions. Report of a National Heart, Lung and Blood Institute/ Office of Rare Diseases Workshop, Circulation, 109, 2947, 10.1161/01.CIR.0000132476.87231.6F Rubin, 2004, Pulmonary arterial hypertension. A look to the future, J Am Coll Cardiol, 43, 89S, 10.1016/j.jacc.2004.02.030